Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Imiquimod vs LLETZ for HSIL
NCT04859361Unknown
- Sponsor
- University Clinical Centre Maribor
- Start
- Nov 2018
- Primary completion
- Apr 2020
- Modality
- Nucleic Acid-Directed Small Molecules, Irreversible Covalent Inhibitors, Metabolically Activated Prodrugs
- Countries
- 1
01
Overview
Randomised, open-label trial of imiquimod in cervical intraepithelial neoplasia (CIN), sponsored by University Clinical Centre Maribor. Primary endpoint: Absence of HSIL at 24 weeks. Status: unknown.
02
Drugs
imiquimod
03
Conditions
cervical intraepithelial neoplasia (CIN)
Beyond the preview
Go deeper on NCT04859361.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04859361.